References
- Abdelmegeed S.M., Mohammed S.: Canine mammary tumors as a model for human disease. Oncol Lett 2018, 15, 8195–8205, doi.org/10.3892/ol.2018.8411.
- Bohrer L.R., Chen S., Hallstrom T.C., Huang H.: Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: A potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology 2010, 151, 5136–5145, doi.org/10.1210/en.2010-0436.
- Boros J., Arnoult N., Stroobant V., Collet J.F., Decottignies A.: Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1alpha at chromatin. Mol Cell Biol 2014, 34, 3662–3674, doi.org/10.1128/MCB.00205-14.
- Canadas A., Franca M., Pereira C., Vilaca R., Vilhena H., Tinoco F., Silva M.J., Ribeiro J., Medeiros R., Oliveira P., Dias-Pereira P, Santos M.: Canine mammary tumors: Comparison of classification and grading methods in a survival study. Vet Pathol 2019, 56, 208–219, doi.org/10.1177/0300985818806968.
- Cardoso C., Mignon C., Hetet G., Grandchamps B., Fontes M., Colleaux L.: The human EZH2 gene: Genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders. Eur J Hum Genet 2000, 8, 174–180, doi.org/10.1038/sj.ejhg.5200439.
- Choi H.J., Lee H.B., Park H.K., Cho S.M., Han H.J., Lee S.J., Lee J.Y., Nam S.J., Cho E.H., Son W.C.: EZH2 expression in naturally occurring canine tumors. Comp Med 2018, 68, 148–155.
- Choi H.J., Jang S., Ryu J.E., Lee H.J., Lee H.B., Ahn W.S., Kim H.J., Lee H.J., Lee H.J., Gong G.Y, Son W.C.: Significance of EZH2 expression in canine mammary tumors. Bmc Vet Res 2016, 12, 164, doi.org/10.1186/s12917-016-0789-2.
- Ding L, Kleer C.G.: Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 2006, 66, 9352-5, doi.org/10.1158/0008-5472.CAN-06-2384.
- Duan R., Du W., Guo W.: EZH2: A novel target for cancer treatment. J Hematol Oncol 2020, 13, 104, doi.org/10.1186/s13045-020-00937-8.
- Eich M.L., Athar M., Ferguson J.R., Varambally S.: EZH2-Targeted Therapies in Cancer: Hype or a Reality. Cancer Res 2020, 80, 5449–5458, doi.org/10.1158/0008-5472.CAN-20-2147.
- Fan Y., Ren X., Liu X., Shi D., Xu E., Wang S., Liu Y.: Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients. Sci Rep 2021, 11, 6651, doi.org/10.1038/s41598-021-85029-4.
- Gao B., Liu X., Li Z., Zhao L., Pan Y.: Overexpression of EZH2/NSD2 histone methyltransferase axis predicts poor prognosis and accelerates tumor progression in Triple-Negative breast cancer. Front Oncol 2020, 10, 600514, doi.org/10.3389/fonc.2020.600514.
- Hobert O., Jallal B., Ullrich A.: Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 1996, 16, 3066–3073, doi.org/10.1128/mcb.16.6.3066.
- Inari H., Suganuma N., Kawachi K., Yoshida T., Yamanaka T., Nakamura Y., Yoshihara M., Nakayama H., Yamanaka A., Masudo K., Oshima T., Yokose T., Rino Y., Shimizu S., Miyagi Y., Masuda M.: Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: Exploratory study using primary and paired metastatic lesions. Bmc Cancer 2017, 17, 160, doi.org/10.1186/s12885-017-3154-3.
- Jang S.H., Lee J.E., Oh M.H., Lee J.H., Cho H.D., Kim K.J., Kim S.Y., Han S.W., Kim H.J., Bae S.B., Lee H.J.: High EZH2 protein expression is associated with poor overall survival in patients with luminal a breast cancer. J Breast Cancer 2016, 19, 53–60, doi.org/10.4048/jbc.2016.19.1.53.
- Kaszak I., Ruszczak A., Kanafa S., Kacprzak K., Krol M., Jurka P.: Current biomarkers of canine mammary tumors. Acta Vet Scand 2018, 60, 66, doi.org/10.1186/s13028-018-0417-1.
- Lutful K.F., Alvarez C.E., Bird R.C.: Canine mammary carcinomas: A comparative analysis of altered gene expression. Vet Sci 2015, 3, doi.org/10.3390/vetsci3010001.
- Margueron R., Reinberg D.: The Polycomb complex PRC2 and its mark in life. Nature 2011, 469, 343–349, doi.org/10.1038/nature09784.
- Mohammad F., Weissmann S., Leblanc B., Pandey D.P., Hojfeldt J.W., Comet I., Zheng C., Johansen J.V., Rapin N., Porse B.T., Tvardovskiy A., Jensen ON., Olaciregui NG., Lavarino C., Sunol M., de Torres C., Mora J., Carcaboso A.M., Helin K.: EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 2017, 23, 483–492, doi.org/10.1038/nm.4293.
- Qiu J., Sharma S., Rollins R.A., Paul T.A.: The complex role of EZH2 in the tumor microenvironment: Opportunities and challenges for immunotherapy combinations. Future Med Chem 2020, 12, 1415–1430, doi.org/10.4155/fmc-2020-0072.
- Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H., Packeisen J., Sewalt RA., Otte A.P., van Diest P.J.: Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003, 5, 481–488, doi.org/10.1016/s1476-5586(03)80032-5.
- Ramadan E.S., Salem N.Y., Emam I.A., Abdelkader N.A., Farghali H.A., Khattab M.S.: MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors. Vet Res Commun 2021, doi.org/10.1007/s11259-021-09861-9.
- Roh J.W., Choi J.E., Han H.D., Hu W., Matsuo K., Nishimura M., Lee J.S., Kwon S.Y., Cho C.H., Kim J., Coleman R.L., Lopez-Bernstein G, Sood AK.: Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biol Ther 2020, 21, 147–156, doi.org/10.1080/15384047.2019.1672455.
- Senhorello I., Terra E.M., Sueiro F., Firmo B.F., Anai L.A., Goloni C., Canavari I.C., Ampuero R., Pereira R.S, Tinucci-Costa M.: Clinical value of carcinoembryonic antigen in mammary neoplasms of bitches. Vet Comp Oncol 2020, 18, 315–323, doi.org/10.1111/vco.12552.
- Song X., Gao T., Wang N., Feng Q., You X., Ye T., Lei Q., Zhu Y., Xiong M., Xia Y., Yang F., Shi Y., Wei Y., Zhang L, Yu L.: Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Sci Rep 2016, 6, 20864, doi.org/10.1038/srep20864.
- Tang X., Zhou T., Shen J., Luo M., Yuan H., Pan D, Li F.: The expression and potential mechanism of EGFR and EZH2 in breast cancer. Gland Surg 2021, 10, 2535–2545, doi.org/10.21037/gs-21-505.
- Valdivia G., Alonso-Diez A., Perez-Alenza D, Pena L.: From conventional to precision therapy in canine mammary cancer: A comprehensive review. Front Vet Sci 2021, 8, 623800, doi.org/10.3389/fvets.2021.623800.
- Valencakova-Agyagosova A., Frischova Z., Sevcikova Z., Hajurka J., Lepej J., Szakallova I., Kredatusova G., Nagy V., Ledecky V.: Determination of carcinoembryonic antigen and cancer antigen (CA 15-3) in bitches with tumours on mammary gland: Preliminary report. Vet Comp Oncol 2014, 12, 205–214, doi.org/10.1111/j.1476-5829.2012.00353.x.
- Vantaku V., Putluri V., Bader DA., Maity S., Ma J., Arnold J.M., Rajapakshe K., Donepudi S.R., von Rundstedt FC., Devarakonda V., Dubrulle J., Karanam B., Mcguire S.E., Stossi F., Jain A.K., Coarfa C., Cao Q., Sikora A.G., Villanueva H., Kavuri S.M., Lotan Y., Sreekumar A, Putluri N.: Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene 2020, 39, 6265– 6285, doi.org/10.1038/s41388-019-0902-7.
- Wang S., Cai L., Zhang F., Shang X., Xiao R, Zhou H.: Inhibition of EZH2 attenuates sorafenib resistance by targeting NOTCH1 Activation-Dependent liver cancer stem cells via NOTCH1-Related MicroRNAs in hepatocellular carcinoma. Transl Oncol 2020, 13, 100741, doi.org/10.1016/j.tranon.2020.01.002.
- Xu J., Wang Z., Lu W., Jiang H., Lu J., Qiu J, Ye G.: EZH2 promotes gastric cancer cells proliferation by repressing p21 expression. Pathol Res Pract 2019, 215, 152374, doi.org/10.1016/j.prp.2019.03.003.